Novel small molecule drugs for the treatment of sleep disorders and depression

UCSF scientists have identified novel small molecules which are selective agonists and inverse agonists of the melatonin receptor types MT1 and MT2. The molecules have high in vitro and in vivo potency and potential to be utilized as a novel therapeutic for treating depression, jet lag, and sleep disorders. Ellen Kats ellen.kats@ucsf.edu 415-758-1598